Shorts are over a barrel. Pps staying strong. Preferred shares will ruin would-be low-ball bidders. It's going to take a king's ransom to get this gem.

Relatively low volume. As of right now down 12 cents. I'm not seeing a big "sell-off"...

That would/should cost a potential partner dearly.

Demand all you want...there will be a long line behind you, so get out of the way.

Website doesn't say phase 1 is"in preparation" yet. Won't be happening anytime soon.

Better to keep 3-71 in the back pocket till we have a revenue stream to pay for developing it ourselves. Then we keep the all the profit.

Frontotemporal Dementia

http://www.anavex.com/u-s-fda-grants-orphan-drug-designation-to-anavex-3-71-for-the-treatment-of-frontotemporal-dementia/

Some interesting points here...

I copied and saved this from this website back on 12/31/16:

http://adpd2017.kenes.com/scientific-information/interactive-program-2#.WGgTpoE76aM

When I go to the website and search this doesn't come up anymore. So the question is: was this a mistake or was it a leak?

If it's a leak, I'm extremely intrigued by the last paragraph. It says the phase 3 trial is being planned. If this is what is going to be released on March 31 then can we expect to still be waiting for the beginning of phase 3 at that time??

Abstract:
15-MONTHS SAFETY AND EXPLORATORY EFFICACY DATA OF ANAVEX 2-73 IN A PHASE 2A STUDY IN MILD-TO-MODERATE ALZHEIMER’S DISEASE PATIENTS

Aims
ANAVEX2-73, a selective sigma-1 and muscarinic receptor agonist was tested in a Phase 2a-study in patients with mild-to-moderate AD. Adverse Events (AEs) were recorded for assessment of safety and maximum tolerated dose (MTD). Cognitive (MMSE, Cogstate, QEEG/ERP) and the functional (ADCS-ADL) marker were measured so as to establish a functional relationship between dosing regimen and exploratory efficacy outcomes.

Method
Thirty-two AD patients 55-85 years old with MMSE 16-28 were recruited. After establishing MTD and dose-response all patients received ANAVEX2-73 between 10mg and 50mg daily orally and re-assessed every 3 months. For safety, mathematical modeling was fitted to the recorded AEs to establish the dose-risk relationship. For efficacy, statistical hypothesis tests were performed on cognitive and functional markers and compared to the corresponding baselines.

Results

Safety: ANAVEX2-73 demonstrated a favorable safety profile in AD patients. The most common AEs were grade 1. Positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities were recorded.

Exploratory Efficacy: 15-months data demonstrate that ANAVEX2-73 preserves average MMSE and ADCS-ADL scores and shows benefits over baseline for Cogstate and QEEG/ERP.

Conclusion
The safety of ANAVEX2-73 was assessed and MTD was determined. Despite not optimal dosing, both cognitive and functional performance is sustained over at least 12 months, suggesting that the effect of the compound does not seem to worsen AD symptoms with repeated dosing. In a progressive degenerative disease this is considered a positive outcome. The data support further clinical development of ANAVEX2-73 and preparation for a larger confirmatory study is underway.


Co-authors
C. Missling 1
1, USA

In perpetuity..! ??

They don't have enough liquid money to buy into it an a meaningful %.

Well...maybe they could all go in together and buy a percent or two...

Besides...who's to say some of the sharks aren't in it already??

The minimum starting bid for AVXL at the point where they are right now...today... IMO would have to be $5B. That is a solid, reasonable offer for the stage they are in right now.

That being said, I think they'd be fools to accept an off of $5B right now, because in less than 2 years the company will be worth many times that amount... again, IMO.

How did they complete their phase two trial with the extremely low expense that they did? Other biotechs aren't able to do that either.

There is a difference with this company. They do more with less and it's because they have a newer, better approach that is sleek and efficient. Going to revolutionize the industry going forward.

Less than 5 weeks till release of 15-month data.

What will we see in the meantime? Unannounced surprise catalysts? Deals? Patent news?

Yes! And that would in fact be the best situation for the investors. Waiting till we are further along will greatly increase our leverage at the negotiating table.

"Future is so bright I have to wear shades"!

Well....there's always the after hours...

You're preaching to the choir.

My point is that we should see something happen with the trials in the next month or two. When that happens, we may get a good move in the right direction with pps.

I agree, but I'm still wondering what the timeframe looks like as stated by the company. I believe they said early this year. That being the case, I'd expect to see the trials starting up by end of March or end of April at the latest.

Hard to wait, but there is a lot happening. Many details to work out.

It would be nice to see them start before data presented on March 31st.

What was the latest "official" word regarding the timing for starting the two trials? Seems like I heard or read that Missling said early in the year...

We are potentially within months of changing the CNS branch of medicine as we know it. When (not if) 2-73 along with Anavex's approach is finally accepted by the mainstream biotech industry, we will see a new Golden Age in medicine...comparable to the invention of Penicillin. And who will lead the charge into this new frontier??? ANAVEX.

Meaningless.

Not to mention... the "gap needs to be filled" idea is complete bull. There is absolutely no reason that it must be filled.

One morning we will gap up to double or even possibly triple digits and there will be no gap filling. If you are waiting on the sidelines that day you will be left behind.

No second chances for chickens.

In your dreams!

Are we going to close GREEN today??

Hey...I thought sophisticated investors said this was going down 20%. Is that going to happen soon? Was "sophisticated" being used as code for "incorrect".

Lol!!

Somebody kicked us down the stairs this morning.

Tomorrow the same people will help us climb back up.

Hold on tight...getting interesting...

Kaboom what?? This was announced weeks ago. The title basically says: "Anavex is working with Rettsyndrome.org to treat Rett."

Where do you suppose we'll be by the March 31 conference?

If you're betting against AVXL I'd be much more worried about the upcoming gap up to double digits...at least double, maybe triple!!

"Gap Theory" is not based on anything. It's a self-fulfilling prophecy. Enough people buy into it and- lo and behold! - next thing you know it fills because of all the orders anticipating it.

Problem is, as soon as it falls off the radar everyone forgets about it and life moves on.

Looking forward to big catalyst on 3/31/17. Imagine where we'll be by then!!

Looking good!!

Retts won't be worth $30 in and of itself. There are just too few cases. Although, it's hard to calculate the value of the psychological effect to investors. Success in this disease would do wonders for PR and the way the company is perceived by the investing community.

It would be amazing to see some kind of relief for sufferers of Rett. Would take your breath away.

I agree with you. A partnership is probably going to need to happen at some point, but the longer it is put off the better the deal is going to be for AVXL.

If we were to get Rett approval first and had some actual revenue coming in we could probably put it off for quite some time. Who knows...if the stock spikes enough before we partner maybe we could go alone all the way with minimal dilution.

Many different scenarios, but most likely that we do partner at some point.

AVXL and Rettsyndrome.org comprise 2/5 of the panel.

I'm not expecting earth-shaking news tomorrow, but it's not out of the question. Could announce start of Rett trial in a PR and then discuss it generally at the conference.

Not likely, but possible IMO

If the doctor wants to talk about any new material developments then we would need a PR.

Tomorrow's stage would be the perfect setting for an announcement of commencement of the Rett trial. Maybe there's a PR coming in the premarket??

Looking forward to continued great news.

Here, here!

Climbing the golden staircase. Every day takes us one step higher.

Can't wait to see the view a year from now!

I don't think so. The conversation was a summary of everything they are doing now and planning for now. He discussed the upcoming trials for Alzheimer's, Parkinson's and Rett. In the same conversation he discussed the financials and stated that there is enough cash for 2 years.